Clinical trials: Neovascular Age-related Macular Degeneration, open to volunteers
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
- Trial name
- NCT07275840
- Testing
- IBI302 8mg dose
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Neovascular Age-related Macular Degeneration(nAMD)
Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD) is one of the main causes of irreversible vision loss in the elderly, characterized by neovascularization and vascular leakage in the macular area, ultimately leading to damage…
- Trial name
- NCT07088445
- Testing
- Faricimab
- Volunteers
- 35 people
- Sponsor
- Hui Peng
Renal Function Disorder, Diabetic Macular Edema (DME)
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients.
- Conditions
- Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
- Trial name
- NCT06929507
- Testing
- Intravitreal injection of Faricimab or Aflibercept 2 mg
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- University Hospital, Alexandroupolis
Neovascular Age-related Macular Degeneration (nAMD)
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related…
- Trial name
- NCT06470373
- Testing
- RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
- Where
- 7 sites in United States
- Volunteers
- 434 people
- Sponsor
- Rophibio, Inc.
Neovascular Age-related Macular Degeneration(nAMD)
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
Age-related macular degeneration (AMD) is a progressive disease leading to severe and irreversible vision loss of which the neovascular AMD (nAMD) accounted for 90% blindness in AMD.
- Trial name
- NCT06031727
- Testing
- HG202
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
This Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Decisions About Treatment for Patients with a Specific Eye Disease (nAMD)
This is a research plan from the University of Munich (LMU) that aims to study how the use of AI reports can impact ophthalmologists' decisions regarding treatment for patients with neovascular age-related macular degeneration…
- Trial name
- LMU ASSIST (NCT06817915)
- Testing
- AI assisted assessment of SD-OCT scans
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Johannes Schiefelbein
Neovascular Age-related Macular Degeneration
Regulatory Post-Marketing Surveillance Study for Brolucizumab
This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.
- Trial name
- NCT04985487
- Testing
- brolucizumab
- Where
- 28 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular (wet) Age-Related Macular Degeneration
The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration
The macula has a very high concentration of photoreceptor cells - the cells that detect light. They send signals to the brain, which interprets them as images.
- Trial name
- it does not (NCT06759597)
- Volunteers
- 50 people
- Sponsor
- Assiut University
Neovascular Age-related Macular Degeneration
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
- Trial name
- NCT06141460
- Testing
- RRG001
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Refreshgene Technology Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial
Age-related macular degeneration (AMD) leads to severe and irreversible vision loss, while neovascular AMD (nAMD) accounts for 80-90% of AMD blindness.
- Trial name
- BRIGHT (NCT06623279)
- Testing
- HG202
- Volunteers
- 15 people
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
Neovascular Age-related Macular Degeneration
Gene Therapy(FT-003) for Wet AMD
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD).
- Trial name
- NCT06492863
- Testing
- FT-003
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Frontera Therapeutics
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study in which they received a single…
- Trial name
- RGX-314 SRLTFU (NCT03999801)
- Testing
- RGX-314
- Where
- 9 sites in United States
- Volunteers
- 865 people
- Sponsor
- AbbVie
Neovascular (Wet) Age-related Macular Degeneration (AMD)
OCT Angiography in Wet AMD
The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2.
- Trial name
- NCT02253030
- Testing
- Optical Coherence Tomography
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Neovascular Age-related Macular Degeneration
Gene Therapy for Wet AMD
FT-003 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly individuals.
- Trial name
- NCT05611424
- Testing
- FT-003
- Volunteers
- 18 people
- Sponsor
- Frontera Therapeutics